NasdaqGS - Delayed Quote • USD
Ultragenyx Pharmaceutical Inc. (RARE)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 19 | 19 |
| Avg. Estimate | -1.75 | -1.64 | -6.45 | -5.04 |
| Low Estimate | -2.04 | -2.01 | -8.32 | -7.05 |
| High Estimate | -1.39 | -1.36 | -5.23 | -1.58 |
| Year Ago EPS | -2.33 | -2.25 | -8.25 | -6.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 15 | 18 | 19 |
| Avg. Estimate | 116.36M | 125.25M | 513.08M | 642.09M |
| Low Estimate | 98.8M | 120.38M | 499.73M | 541.73M |
| High Estimate | 124.6M | 130.1M | 530.01M | 920.7M |
| Year Ago Sales | 100.5M | 108.31M | 434.25M | 513.08M |
| Sales Growth (year/est) | 15.80% | 15.60% | 18.20% | 25.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.98 | -2.07 | -2.08 | -1.62 |
| EPS Actual | -2.33 | -2.25 | -2.23 | -1.52 |
| Difference | -0.35 | -0.18 | -0.15 | 0.1 |
| Surprise % | -17.70% | -8.70% | -7.20% | 6.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.75 | -1.64 | -6.45 | -5.04 |
| 7 Days Ago | -1.76 | -1.64 | -6.45 | -4.97 |
| 30 Days Ago | -1.76 | -1.63 | -6.44 | -4.96 |
| 60 Days Ago | -1.76 | -1.63 | -6.43 | -4.79 |
| 90 Days Ago | -1.65 | -1.58 | -6.21 | -4.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | RARE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 24.90% | -- | -- | 1.50% |
| Next Qtr. | 27.10% | -- | -- | 11.40% |
| Current Year | 21.80% | -- | -- | 5.20% |
| Next Year | 21.90% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 8.90% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | TD Cowen: Buy to Buy | 4/24/2024 |
| Initiated | RBC Capital: Outperform | 4/22/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 4/17/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 4/16/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/18/2024 |
Related Tickers
AGIO Agios Pharmaceuticals, Inc.
31.67
-0.44%
BPMC Blueprint Medicines Corporation
92.26
-0.03%
MREO Mereo BioPharma Group plc
2.7800
0.00%
SWTX SpringWorks Therapeutics, Inc.
43.38
-1.41%
PTCT PTC Therapeutics, Inc.
25.21
-0.79%
SAGE Sage Therapeutics, Inc.
14.00
+8.11%
FGEN FibroGen, Inc.
0.9843
-8.01%
DAWN Day One Biopharmaceuticals, Inc.
15.19
-8.71%
LEGN Legend Biotech Corporation
45.17
-4.81%
PTGX Protagonist Therapeutics, Inc.
25.70
-4.28%